Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 12 Researches
7.9
USERS' SCORE
Good
Based on 2 Reviews
8.4
Supplement Facts
Serving Size: 1 Lozenge
Amount Per Serving
%DV
Calories
<5
Total Carbohydrate
<1 g
<1%**
Total Sugars
0 g
†
Includes 0 g Added Sugars
0%**
Xylitol
<1 g
†
Vitamin C (as Ascorbic Acid)
100 mg
111%
Zinc (elemental) (from 15 mg Zinc Bisglycinate) (TRAACS™)
3 mg
27%
Elderberry (10:1 Concentrate)(Sambucus nigra) (Fruit)
150 mg
†
Top Medical Research Studies
9
We explored the effects of vitamin C on lung cancer, particularly its ability to inhibit pulmonary metastasis—meaning the spread of cancer to the lungs. Using an H22 pulmonary metastasis mouse model, we observed that vitamin C administration, both intraperitoneally and orally, showed promising results.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
7
We examined the connection between vitamin C consumption and lung cancer risk by analyzing various cohort studies. Our investigation included data from 20 different studies, covering both dietary and supplementary forms of vitamin C, utilizing information collected up until April 2022.
Interestingly, when we looked at all the studies together, we found no significant link between vitamin C intake—whether from food or supplements—and the risk of developing lung cancer. The overall analysis indicated a relative risk of 0.90, close to no effect at all.
However, our subgroup analysis revealed something noteworthy. We observed that individuals who consumed dietary vitamin C showed a significant decrease in lung cancer risk, with a relative risk of 0.82. On the other hand, supplementary vitamin C didn't provide any benefits, with a relative risk of 1.01, suggesting no protective effects.
This suggests that while vitamin C from our diet may help reduce lung cancer risk, vitamin C supplements are unlikely to have the same effect. We should consider focusing on dietary sources of this vitamin for potential lung health benefits.
Interestingly, when we looked at all the studies together, we found no significant link between vitamin C intake—whether from food or supplements—and the risk of developing lung cancer. The overall analysis indicated a relative risk of 0.90, close to no effect at all.
However, our subgroup analysis revealed something noteworthy. We observed that individuals who consumed dietary vitamin C showed a significant decrease in lung cancer risk, with a relative risk of 0.82. On the other hand, supplementary vitamin C didn't provide any benefits, with a relative risk of 1.01, suggesting no protective effects.
This suggests that while vitamin C from our diet may help reduce lung cancer risk, vitamin C supplements are unlikely to have the same effect. We should consider focusing on dietary sources of this vitamin for potential lung health benefits.
8
Vitamin C shows potential in lung cancer
We investigated the effects of pharmacological ascorbate, a form of vitamin C at high concentrations, on non-small cell lung cancer (NSCLC). Our research focused on how P-AscH interacts with cancer cells and uncovers the mechanisms behind its potential benefits.
Through our experiments, we observed that treatment with P-AscH causes oxidative stress in cancer cells. This stress leads to disruptions in their energy production, triggering a cascade of events that results in cell death and a decrease in their ability to survive cloning.
One key finding of our study is that P-AscH appears to target DNA and the cellular responses that repair DNA damage. We found that levels of DNA damage markers increased as a result of P-AscH treatment, while DNA repair mechanisms were found to be misaligned. Notably, using a substance called catalase alongside P-AscH reversed some of these damaging effects, indicating that hydrogen peroxide—a byproduct of P-AscH—plays a significant role in the process.
Overall, our research sheds light on the promising role of pharmacological ascorbate as a potential treatment for lung cancer. This could pave the way for new therapeutic strategies aimed at improving outcomes for patients with NSCLC.
Through our experiments, we observed that treatment with P-AscH causes oxidative stress in cancer cells. This stress leads to disruptions in their energy production, triggering a cascade of events that results in cell death and a decrease in their ability to survive cloning.
One key finding of our study is that P-AscH appears to target DNA and the cellular responses that repair DNA damage. We found that levels of DNA damage markers increased as a result of P-AscH treatment, while DNA repair mechanisms were found to be misaligned. Notably, using a substance called catalase alongside P-AscH reversed some of these damaging effects, indicating that hydrogen peroxide—a byproduct of P-AscH—plays a significant role in the process.
Overall, our research sheds light on the promising role of pharmacological ascorbate as a potential treatment for lung cancer. This could pave the way for new therapeutic strategies aimed at improving outcomes for patients with NSCLC.
Most Useful Reviews
8
Boosts immunity
Very delicious vitamins, the Immune Cocktail, is effective against the initial signs of ARVI. Elderberry acts as a natural immunity enhancer, containing anthocyanin pigments that stimulate immune function and exhibit antiviral properties. The formulation includes vitamin C and zinc. Vitamin C (ascorbic acid) promotes interferon protein production, possesses anti-inflammatory properties, and aids in neutralising free radicals, thereby protecting lung cells from harm. Zinc, according to recent findings, inhibits coronavirus multiplication by blocking the activities of the RNA polymerase and ACE2 enzymes, which facilitate the virus's entry into cells. If you find my review useful, please click "Yes" 
. Happy shopping on iHerb!
. Happy shopping on iHerb!8
Supports immune response
Zinc is a remarkable substance that influences all aspects of the human immune system. Vitamin C is a noted immunostimulant, enhancing the production of interferon proteins that are essential in combating viruses. It has anti-inflammatory effects, assists in neutralising free radicals, and protects lung cells from their damaging impact.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 12 Researches
7.9
- All Researches
9
We explored how high-dose ascorbic acid, commonly known as vitamin C, can enhance the effectiveness of anti-PD1 therapy in treating non-small cell lung cancer (NSCLC). Through a combination of laboratory and animal studies, we aimed to understand if this vitamin could help overcome challenges that some patients face with immunotherapy resistance.
Our findings showed that when we pretreat lung cancer cells with high doses of vitamin C, they become more sensitive to the immune system's attacks. Specifically, we observed that vitamin C intensified the ability of CD8+ T cells—key players in the body's immune response—to destroy cancer cells. The results were particularly striking when vitamin C was combined with anti-PD1 therapy, significantly boosting tumor-killing effects and enhancing immune activity.
Additionally, our analysis revealed that vitamin C treatment altered various immune-related pathways, potentially improving the overall anti-tumor response. This suggests that high-dose vitamin C could serve as a valuable ally in lung cancer therapy, particularly in aiding the effects of established immunotherapies like anti-PD1.
The insights from this study could lead to new strategies for enhancing treatment options for patients battling lung cancer, promising a more effective approach in utilizing immune therapies.
Our findings showed that when we pretreat lung cancer cells with high doses of vitamin C, they become more sensitive to the immune system's attacks. Specifically, we observed that vitamin C intensified the ability of CD8+ T cells—key players in the body's immune response—to destroy cancer cells. The results were particularly striking when vitamin C was combined with anti-PD1 therapy, significantly boosting tumor-killing effects and enhancing immune activity.
Additionally, our analysis revealed that vitamin C treatment altered various immune-related pathways, potentially improving the overall anti-tumor response. This suggests that high-dose vitamin C could serve as a valuable ally in lung cancer therapy, particularly in aiding the effects of established immunotherapies like anti-PD1.
The insights from this study could lead to new strategies for enhancing treatment options for patients battling lung cancer, promising a more effective approach in utilizing immune therapies.
9
We explored the effects of vitamin C on lung cancer, particularly its ability to inhibit pulmonary metastasis—meaning the spread of cancer to the lungs. Using an H22 pulmonary metastasis mouse model, we observed that vitamin C administration, both intraperitoneally and orally, showed promising results.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
9
We investigated a cutting-edge approach that uses zinc-based compounds alongside other treatments to enhance the effects of radiotherapy in lung cancer, specifically non-small-cell lung cancer (NSCLC). The study introduced a radio-immuno-enhancer known as ZnO-Au@mSiO, which plays a dual role as a radiosensitizer and an immune activator.
This innovative enhancer not only targets and induces the death of cancer cells through radiation but also aims to invigorate the immune system. We observed that the combined effects of zinc with gold nanoparticles help bring "exhausted" T cells back into action by promoting immunogenic cell death and targeting immune checkpoints like PD-1 and PD-L1.
Importantly, results demonstrated that using this radio-immuno-enhancer led to a significant increase in protective immune responses, especially the levels of cytotoxic T cells and helper T cells. However, it's crucial to note that while zinc was a component of this treatment strategy, it was evaluated in conjunction with other agents, making it difficult to assess its standalone effectiveness for lung cancer.
This innovative enhancer not only targets and induces the death of cancer cells through radiation but also aims to invigorate the immune system. We observed that the combined effects of zinc with gold nanoparticles help bring "exhausted" T cells back into action by promoting immunogenic cell death and targeting immune checkpoints like PD-1 and PD-L1.
Importantly, results demonstrated that using this radio-immuno-enhancer led to a significant increase in protective immune responses, especially the levels of cytotoxic T cells and helper T cells. However, it's crucial to note that while zinc was a component of this treatment strategy, it was evaluated in conjunction with other agents, making it difficult to assess its standalone effectiveness for lung cancer.
8
We examined the effects of vitamin C, specifically pharmacological ascorbate, when used alongside a new drug called rucosopasem manganese (RUC) in the treatment of non-small cell lung cancer (NSCLC). The study revealed that this combination not only radio-sensitizes the cancer cells but also amplifies the levels of harmful free radicals known as hydroxyl radicals in the cells.
Importantly, we found that this dual approach did not harm normal lung cells, making it a promising strategy. Furthermore, when used together, RUC and vitamin C exhibited greater cancer-fighting properties than either agent alone. Our findings indicated that these treatments work synergistically, supporting the idea that a well-timed combination therapy could make standard treatments like chemotherapy more effective.
In experiments with NSCLC cells and tumor models, RUC and vitamin C showed substantial improvements in overall survival rates. This suggests that harnessing the unique oxidative environments of cancer cells can lead to enhanced anticancer effects. While our results are encouraging, it’s crucial to note that the study emphasized the specific combination's efficacy rather than isolated effects of vitamin C alone, leaving its independent role less clear.
Importantly, we found that this dual approach did not harm normal lung cells, making it a promising strategy. Furthermore, when used together, RUC and vitamin C exhibited greater cancer-fighting properties than either agent alone. Our findings indicated that these treatments work synergistically, supporting the idea that a well-timed combination therapy could make standard treatments like chemotherapy more effective.
In experiments with NSCLC cells and tumor models, RUC and vitamin C showed substantial improvements in overall survival rates. This suggests that harnessing the unique oxidative environments of cancer cells can lead to enhanced anticancer effects. While our results are encouraging, it’s crucial to note that the study emphasized the specific combination's efficacy rather than isolated effects of vitamin C alone, leaving its independent role less clear.
8
We explored the impact of high-dose intravenous vitamin C (IVC) on non-small cell lung cancer (NSCLC) through a comprehensive study. Our investigation focused on understanding how gene expression changes in NSCLC cells when treated with this vitamin. We used advanced RNA sequencing techniques to identify significant genetic alterations in cells exposed to pharmacological levels of vitamin C.
Notably, we discovered two specific genes, SERPINE1 and SERPINB7, that showed reduced expression after vitamin C treatment. By linking patient data from our study and established databases, we found that low levels of these genes were associated with poorer survival outcomes in NSCLC patients receiving standard treatments. However, when patients included IVC alongside their standard care, higher levels of these genes correlated with longer overall survival.
These findings suggest that SERPINE1 and SERPINB7 could serve as potential biomarkers to predict how well patients respond to vitamin C treatments in addition to their usual care for lung cancer. While more research is needed to validate these results further, our exploration indicates promising avenues for enhancing treatment strategies in NSCLC.
Notably, we discovered two specific genes, SERPINE1 and SERPINB7, that showed reduced expression after vitamin C treatment. By linking patient data from our study and established databases, we found that low levels of these genes were associated with poorer survival outcomes in NSCLC patients receiving standard treatments. However, when patients included IVC alongside their standard care, higher levels of these genes correlated with longer overall survival.
These findings suggest that SERPINE1 and SERPINB7 could serve as potential biomarkers to predict how well patients respond to vitamin C treatments in addition to their usual care for lung cancer. While more research is needed to validate these results further, our exploration indicates promising avenues for enhancing treatment strategies in NSCLC.
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
8
Boosts immunity
Very delicious vitamins, the Immune Cocktail, is effective against the initial signs of ARVI. Elderberry acts as a natural immunity enhancer, containing anthocyanin pigments that stimulate immune function and exhibit antiviral properties. The formulation includes vitamin C and zinc. Vitamin C (ascorbic acid) promotes interferon protein production, possesses anti-inflammatory properties, and aids in neutralising free radicals, thereby protecting lung cells from harm. Zinc, according to recent findings, inhibits coronavirus multiplication by blocking the activities of the RNA polymerase and ACE2 enzymes, which facilitate the virus's entry into cells. If you find my review useful, please click "Yes" . Happy shopping on iHerb!
. Happy shopping on iHerb!8
Supports immune response
Zinc is a remarkable substance that influences all aspects of the human immune system. Vitamin C is a noted immunostimulant, enhancing the production of interferon proteins that are essential in combating viruses. It has anti-inflammatory effects, assists in neutralising free radicals, and protects lung cells from their damaging impact.
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Kim HS, Kwon SH, Choi OK, Lim T. High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer and models. Front Immunol. 2024;15:1512605. doi:10.3389/fimmu.2024.1512605
- Pulliam CF, Fath MA, Sho S, Johnson ST, Wagner BA, et al. Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of HO. Redox Biol. 2025;80:103505. doi:10.1016/j.redox.2025.103505
- Munef A, Lafi Z, Shalan N. Investigating anti-cancer activity of dual-loaded liposomes with thymoquinone and vitamin C. Ther Deliv. 2024;15:267. doi:10.4155/tde-2023-0140
- Man S, Bi J, Liu F, Xie W, Ma L. Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway. Mol Nutr Food Res. 2024;68:e2300706. doi:10.1002/mnfr.202300706
- Tran DV, Luu XQ, Tran HTT, Myung SK. Dietary and supplementary vitamin C intake and the risk of lung cancer: A meta‑analysis of cohort studies. Oncol Lett. 2024;27:10. doi:10.3892/ol.2023.14144
- Ou J, Liao Q, Du Y, Xi W, Meng Q, et al. SERPINE1 and SERPINB7 as potential biomarkers for intravenous vitamin C treatment in non-small-cell lung cancer. Free Radic Biol Med. 2023;209:96. doi:10.1016/j.freeradbiomed.2023.10.391
- Sanookpan K, Chantaravisoot N, Kalpongnukul N, Chuenjit C, Wattanathamsan O, et al. Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage. Antioxidants (Basel). 2023;12. doi:10.3390/antiox12091775
- Wang N, Ali A, Liu Z, Chi H, Lv Z, et al. Monofunctional dimetallic Ru(η6-arene) complexes inhibit NOTCH1 signaling pathway and synergistically enhance anticancer effect in combination with cisplatin or vitamin C. Eur J Med Chem. 2023;258:115536. doi:10.1016/j.ejmech.2023.115536
- Le Thi Hong H, Nguyen Van H, Hoang Tuan D, Tran Quang H, Dang Thanh T, et al. Syntheses, structures and anti-cancer activities of Cu and Zn complexes containing 1,1'-[(3-fluoro-phen-yl)methyl-ene]bis-[3-(3-fluoro-phen-yl)imidazo[1,5-]pyridine]. Acta Crystallogr E Crystallogr Commun. 2025;81:47. doi:10.1107/S2056989024011617
- Burger N, Mittenbühler MJ, Xiao H, Shin S, Wei SM, et al. The human zinc-binding cysteine proteome. Cell. 2025;188:832. doi:10.1016/j.cell.2024.11.025
- Xu M, Xu C, Qiu Y, Feng Y, Shi Q, et al. Zinc-based radioenhancers to activate tumor radioimmunotherapy by PD-L1 and cGAS-STING pathway. J Nanobiotechnology. 2024;22:782. doi:10.1186/s12951-024-02999-z
- Wang D, Qiu CJ, Chu Y, Zhang A, Huang R, et al. A Polymeric Vesicle System for Combined Lung Cancer Therapy through Chemotherapy and Vasculature Normalization. Biomater Res. 2024;28:0117. doi:10.34133/bmr.0117
